Drugs / Cerebral Dopamine Neurotrophic Factor
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03775538 | Jul 2018 → Jul 2020 | Parkinson disease, movement disorder, neurodegenerative disease | Herantis Pharma Plc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03295786 | Sep 2017 → Dec 2019 | Parkinson disease, movement disorder, neurodegenerative disease | Herantis Pharma Plc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-09-19 | Herantis Pharma Plc. | Results Herantis Pharma: Structural rationale of HER-096 design published in Nature Communications herantis.com ↗
This study demonstrates that this molecular interaction with GRP78, the master regulator of the unfolded protein response pathway, is required for CDNF’s neuroprotective effects. |
| 2021-10-26 | Herantis Pharma Plc. | Results Herantis Pharma Provides R&D Update and Information About New Biomarker Program herantis.com ↗
Strong data on impact of rhCDNF on disease biomarkers including an update on clinical follow-up study |
| 2021-09-09 | Herantis Pharma Plc. | Results Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology herantis.com ↗
Initial results from the Nanoform PoC project show that the nanoforming process can be successfully applied to rhCDNF. |
| 2020-08-27 | Herantis Pharma Plc. | Results Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months herantis.com ↗
Treatment Emergent Adverse Events (TEAE) were generally mild and transient, and reduced compared to the first period. |
All press releases naming this drug 6 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-19 | Herantis Pharma Plc. | Herantis Pharma: Structural rationale of HER-096 design published in Nature Communications herantis.com ↗ |
| 2021-10-26 | Herantis Pharma Plc. | Herantis Pharma Provides R&D Update and Information About New Biomarker Program herantis.com ↗ |
| 2021-09-09 | Herantis Pharma Plc. | Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology herantis.com ↗ |
| 2020-09-11 | Herantis Pharma Plc. | Registration Information for Herantis Pharma’s Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout herantis.com ↗ |
| 2020-09-04 | Herantis Pharma Plc. | Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout herantis.com ↗ |
| 2020-08-27 | Herantis Pharma Plc. | Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months herantis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cerebral Dopamine Neurotrophic Factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03295786 ↗ |
| Route | Other | “Repeated intracerebral infusions” NCT03295786 ↗ |